Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi‐institutional consortium-Reference-Cited by-同舟云学术

Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi‐institutional consortium

Published:2023-08-21 Issue:10 Volume:45 Page:2627-2637
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Id Said Badr¹^ORCID,Mutsaers Adam¹,Chen Hanbo¹,Husain Zain A.¹,Biswas Tithi²,Dagan Roi³^ORCID,Erler Darby¹,Foote Matthew⁴,Louie Alexander V.¹,Redmond Kristin⁵,Ricardi Umberto⁶,Sahgal Arjun¹,Poon Ian¹^ORCID

Affiliation:

1. Department of Radiation Oncology, Odette Cancer Centre Sunnybrook Health Science Centre Toronto Ontario Canada

2. Department of Radiation Oncology University Hospitals Seidman Cancer Center Cleveland Ohio USA

3. University of Florida Health Proton Therapy Institute Jacksonville Florida USA

4. Department of Radiation Oncology, Princess Alexandra Hospital University of Queensland Brisbane Queensland Australia

5. Department of Radiation Oncology and Molecular Radiation Sciences Johns Hopkins University School of Medicine Baltimore Maryland USA

6. Department of Oncology University of Turin Turin Italy

Abstract

AbstractBackgroundWe report the results of an international multi‐institutional cohort of oligometastatic (OMD) head and neck cancer (HNC) patients treated with SBRT.MethodsPatients with OMD HNC (≤5 metastases) treated with SBRT between 2008 and 2016 at six institutions were included. Treated metastasis control (TMC), progression‐free survival (PFS), and overall survival (OS) were analyzed by multivariable analysis (MVA).ResultsForty‐two patients with 84 HNC oligometastases were analyzed. The TMC rate at 1 and 2 years were 80% and 66%, with a median time to recurrence of 10.1 months. The median PFS and OS were 4.7 and 23.3 months. MVA identified a PTV point maximum (BED)10 > 100 Gy as a predictor of improved TMC (HR = 0.31, p = 0.034), and a cumulative PTV > 48 cc as having worse PFS (HR = 2.99, p < 0.001).ConclusionFavorable TMC and OS was observed in OMD HNCs treated with SBRT.

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27488

Reference46 articles.

1. Epidemiology and Demographics of the Head and Neck Cancer Population

2. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

3. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients

4. Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival

5. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel prognostic score (HAMP) for head and neck cancer patients with single and multiple SBRT‐treated lung metastases derived from retrospective analyses of survival outcome;Head & Neck;2024-08-08

2. Survival, Treatment Outcome, and Safety of Multiple and Repeated Courses of Stereotactic Body Radiotherapy for Pulmonary Oligometastases of Head and Neck Squamous Cell Carcinoma;Cancers;2023-11-01